This inventor holds 3 USPTO granted patents. Top assignee: Kali-Chemie Pharma Gmbh. Active years: 1992-1997.
Location History:
- Wienhausen, DE (1992)
- Moenchengladbach, DE (1996 - 1997)
Company Filing History:
Years Active: 1992-1997
Title: Arman Farjam: Innovator in Cardiac Treatment
Introduction
Arman Farjam is a notable inventor based in Moenchengladbach, Germany. He has made significant contributions to the field of cardiac treatment through his innovative research and development of new compounds. With a total of 3 patents, Farjam is recognized for his work in addressing heart rhythm disorders.
Latest Patents
Farjam's latest patents focus on the treatment of heart rhythm disorders. One of his key inventions involves the use of 3,7,9,9-tetrasubstituted 3-phenylsulfonyl-3,7-diazabicyclo[3.3.1]nonane compounds for treating cardiac arrhythmias in larger mammals, including humans. Additionally, he has developed novel antiarrhythmically active compounds corresponding to a specific general formula, where R¹ is an alkyl group having 1-6 carbon atoms or a cycloalkylalkyl group having 4-7 carbon atoms.
Career Highlights
Arman Farjam is currently employed at Kali-Chemie Pharma GmbH, where he continues to advance his research in pharmacology. His work has been instrumental in developing effective treatments for cardiac conditions, showcasing his dedication to improving patient outcomes.
Collaborations
Farjam collaborates with esteemed colleagues such as Uwe Schoen and Dieter Ziegler. Their combined expertise enhances the innovative efforts within their research team.
Conclusion
Arman Farjam stands out as a significant figure in the field of cardiac treatment, with his innovative patents paving the way for advancements in medical science. His contributions are vital for the ongoing development of effective therapies for heart rhythm disorders.